|
Match
|
Document |
Document Title |
|
|
7618949 |
Drug-eluting stents coated with P2Y12 receptor antagonist compound
The present invention provides a P2Y 12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y 12 receptor antagonist compounds or a pharmaceutically...
|
|
|
7612047 |
Degradation-resistant mononucleoside phosphate compounds
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that...
|
|
|
7608600 |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention...
|
|
|
7608599 |
Antiviral phosphoramidates
The invention provides novel nucleoside compounds of formula I wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5 R 6 , R 8a , R 9 and R 10 are as defined herein which are useful for the treatment of...
|
|
|
7608597 |
Methods and compositions for treating hepatitis C virus
A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a...
|
|
|
7592326 |
Method for stimulating the immune, inflammatory or neuroprotective response
Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune...
|
|
|
7582616 |
Nucleoside transport inhibitors
Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases.
|
|
|
7576068 |
Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus
This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention...
|
|
|
7569555 |
Method for stimulating the immune, inflammatory or neuroprotective response
Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune...
|
|
|
7566703 |
Semi-soft C-class immunostimulatory oligonucleotides
The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for...
|
|
|
7557093 |
Composition for promoting collagen production
The invention provides a composition for promoting collagen production, and more specifically, provides a composition capable of promoting collagen production in human dermis. Further, the...
|
|
|
7517862 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7468357 |
Nucleosides with anti-hepatitis B virus activity
A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-nucleotide, optionally...
|
|
|
7452870 |
Drug-eluting stents coated with P2Y12 receptor antagonist compound
The present invention provides a P2Y 12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y 12 receptor antagonist compounds or a pharmaceutically...
|
|
|
7439349 |
Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof
Method for producing large lots of final sterile Poly-ICLC suitable for clinical use with reduced toxicity at effective dose levels, and method for using Poly-ICLC to regulate genes, and method for...
|
|
|
7435724 |
Degradation-resistant mononucleoside phosphate compounds
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that...
|
|
|
7429571 |
Therapeutic furopyrimidines and thienopyrimidines
The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are...
|
|
|
7429569 |
Compositions and methods for the regulation of homocysteine levels within the body
Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that...
|
|
|
7425546 |
Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such...
|
|
|
7399754 |
N2-quinoline or isoquinoline substituted purine derivatives
Novel compound having the following formula:
wherein W represents a hydrogen, an optionally substituted C 1-6 alkyl, an optionally substituted C 3-6 cycloalkyl, or an optionally substituted C...
|
|
|
7396825 |
Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A 2A adenosine...
|
|
|
7354907 |
Short immunomodulatory oligonucleotides
The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The...
|
|
|
7323453 |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
The present invention provides methods of inhibiting orthopoxvirus replication and/or treating orthopoxvirus infection with certain nucleoside compounds and derivatives thereof. These compounds are...
|
|
|
7323452 |
Method for the accelerated in vivo removal of ethanol
A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as...
|
|
|
7304043 |
β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active...
|
|
|
7256183 |
Method for treating or preventing inflammatory diseases
The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel...
|
|
|
7247621 |
Antiviral phosphonate compounds and methods therefor
Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the...
|
|
|
RE39573 |
Antimutagenic compositions for treatment and prevention of photodamage to skin
A method of improving DNA repair and reducing DNA damage and for reducing mutation frequency in skin for the purpose of reducing consequences of exposure to solar or ultraviolet radiation is...
|
|
|
RE39497 |
Storage of materials
A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be...
|
|
|
7169765 |
Acyl deoxyribonucleoside derivatives and uses thereof
The invention relates to compositions comprising acyl derivatives of 2′-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and...
|
|
|
7157449 |
Medicament for the treatment of diseases caused by parasitic protozoa
The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of...
|
|
|
7153877 |
Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and...
|
|
|
7153840 |
Aqueous fludarabine phosphate composition
This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which...
|
|
|
7148207 |
Oral fludara of high-purity formulation with quick release of active ingredient
This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
|
|
|
7132408 |
Composition and method for inhibiting platelet aggregation
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The...
|
|
|
7119110 |
Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and...
|
|
|
7115585 |
Compositions for treating epithelial and retinal tissue diseases
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that...
|
|
|
7115579 |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the...
|
|
|
7109181 |
Joint lubrication with P2Y purinergic receptor agonists
The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises...
|
|
|
7105497 |
Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such...
|
|
|
7105495 |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the...
|
|
|
7101860 |
Composition and method for inhibiting platelet aggregation
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The...
|
|
|
7091190 |
Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically...
|
|
|
7084128 |
Method for reducing intraocular pressure
The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a...
|
|
|
7084126 |
Methods and compositions for enhancing cellular function through protection of tissue components
Methods and composisions for enhancing cellular function through protection of a tissue components such receptors, proteins, lipids, nucleic acids, carbohydrates, hormones, vitamins, and cofactors,...
|
|
|
7081449 |
Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′...
|
|
|
7071173 |
Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine
A method for treatment of HBV and HIV infections comprising administering the compound or salt of formula Ig
|
|
|
7056894 |
Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases, and uses thereof
The present invention provides compounds having the formula:
wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are...
|
|
|
7053064 |
Compounds for the treatment of tobacco dependence and withdrawal
The invention provides methods for treating or suppressing tobacco or nicotine usage or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or...
|
|
|
7049303 |
Inhibition of viruses
Disclosed is a pharmaceutical composition comprising a ribonucleoside analogue in accordance with general formula I or II as herein defined, in admixture with a physiologically acceptable excipient...
|